查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1842107

全球HPV相关疾病市场：市场规模、份额和趋势分析（按类型、治疗方法、分销管道和地区划分），细分市场预测（2025-2033年）

HPV Associated Disorders Market Size, Share & Trends Analysis Report By Type, (Cervical Intraepithelial Neoplasia (CIN), Cervical Cancer), By Treatment (Vaccines, Anti-viral Drugs), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

HPV相关疾病：市场概览

全球 HPV 相关疾病市场预计在 2024 年达到 185 亿美元，预计到 2033 年将达到 285 亿美元，2025 年至 2033 年的复合年增长率为 4.9%。

由于全球HPV感染病例的不断增加，该产业正经历强劲成长。

持续性HPV感染被认为是子宫颈癌、肛门癌、外阴癌、阴道癌、阴茎癌和口咽癌的主要原因之一，因此需要及时诊断和治疗。能够准确检测高风险HPV病毒株的分子诊断检测需求日益增长，推动了其在临床中的应用，同时医疗系统也优先开展筛检项目，以早期发现癌前病变。例如，根据世界卫生组织（WHO）2024年3月的一项研究，人类乳突病毒（HPV）包含约200种已知病毒类型。虽然大多数感染是无害的，但某些高危险型HPV会引起生殖器湿疣和各种癌症。约90%的病例中，人体可自然清除感染。据估计，2019年HPV导致约62万例女性癌症和7万例男性癌症。到2022年，子宫颈癌将成为女性第四大癌症死因，全球整体新增病例达66万例，死亡人数达35万人。子宫颈癌占女性所有HPV相关癌症的90%以上。这些数据凸显了HPV相关疾病在全球范围内造成的巨大负担，并推动了对先进诊断技术和有效治疗的需求。

治疗方案的进步是HPV相关疾病市场的另一个大成长动力。包括免疫疗法和标靶药物在内的创新治疗方法正日益受到关注，因为它们能够改善HPV诱发恶性肿瘤患者的预后。製药公司正大力投资研发，以期将新型治疗方法推向市场并强化其治疗产品线。例如，2025年4月，BioMed Central Ltd.的研究人员报告称，人类乳突病毒（HPV）这种DNA病毒已被证实是子宫颈癌、外阴癌、阴道癌、阴茎癌、肛门癌以及头颈癌的致病因素。他们指出，持续感染以及某些HPV基因型的致癌性是大多数HPV相关癌症的驱动因子。

目录

第一章 分析方法和范围

第二章执行摘要

第三章：HPV相关疾病市场：驱动因素、趋势与范围

  • 市场联动展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析：波特五力分析
    • PESTEL 分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章 HPV相关疾病市场：按类型分類的业务分析

  • 按类型分類的市场份额（2024 年和 2033 年）
  • 按类型分類的仪表板
  • 按类型分類的市场规模预测和趋势分析（2021-2033）
  • 子宫颈上皮内瘤（CIN）
  • 子宫颈癌
  • 肛门上皮内瘤（AIN）
  • 肛门癌
  • 生殖器疣
  • 其他的

第五章 HPV相关疾病市场：依治疗方法的业务分析

  • 按治疗方法的市场份额（2024 年和 2033 年）
  • 治疗方法专用仪表板
  • 按治疗方法的市场规模预测和趋势分析（2021-2033 年）
  • 疫苗
  • 抗病毒药物
  • 其他的

第六章：HPV相关疾病市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2024 年和 2033 年）
  • 分销通路仪錶板
  • 按分销管道分類的市场规模预测和趋势分析（2021-2033）
  • 医院药房
  • 零售药房
  • 其他的

第七章 HPV相关疾病市场：区域估算与趋势分析

  • 按地区分類的市场份额分析（2024 年和 2033 年）
  • 市场概览：按地区
  • 市场规模预测及趋势分析（2021-2033）
  • 北美洲
    • 按国家/地区划分（2021-2033 年）
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与企业概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Merck &Co., Inc.
    • GlaxoSmithKline plc
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc.
    • AstraZeneca
    • Biocon
    • Lilly
    • AbbVie Inc.
Product Code: GVR-3-68038-436-9

HPV Associated Disorders Market Summary

The global HPV associated disorders market size was estimated at USD 18.5 billion in 2024 and is projected to reach USD 28.5 billion by 2033, growing at a CAGR of 4.9% from 2025 to 2033. The industry is witnessing strong growth due to the rising prevalence of HPV infections worldwide.

Persistent HPV infections are recognized as a major cause of cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers, which has increased the need for timely diagnosis and treatment. Growing demand for molecular diagnostic tests that can accurately detect high-risk HPV strains is fueling adoption in clinical settings, while healthcare systems are prioritizing screening programs to identify precancerous changes early. For instance, in March 2024, World Health Organization findings indicated that human papillomavirus (HPV) encompassed a group of around 200 known viruses, with most infections remaining harmless while some high-risk types caused genital warts and various cancers. In approximately 90% of cases, the body naturally cleared the infection. In 2019, HPV was estimated to have caused about 620,000 cancer cases in women and 70,000 in men. Cervical cancer became the fourth leading cause of cancer among women in 2022, with 660,000 new cases and 350,000 deaths globally. Cervical cancers represented over 90% of all HPV-related cancers in women. These figures highlight the substantial global burden of HPV-related disease, strengthening the demand for advanced diagnostics and effective treatments.

Advancements in treatment solutions represent another major growth driver for the HPV associated disorders market. Innovative therapies, including immunotherapies and targeted drugs, are gaining traction as they provide improved outcomes for patients with HPV-driven malignancies. Pharmaceutical companies are investing heavily in research and development to bring novel therapies into the landscape, strengthening the treatment pipeline. For instance, in April 2025, authors at BioMed Central Ltd. reported that human papillomavirus (HPV), a DNA virus, had been established as a causative agent of cervical, vulvar, vaginal, penile, anal, and head & neck cancers. They noted that persistent infection and the oncogenic potential of certain HPV genotypes drove most HPV-related cancers.

Global HPV Associated Disorders Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Cervical Intraepithelial Neoplasia (CIN)
  • Cervical Cancer
  • Anal Intraepithelial Neoplasia (AIN)
  • Anal Cancer
  • Genital Warts
  • Others
  • Treatment Outlook (Revenue, USD Million, 2021 - 2033)
  • Vaccines
  • Anti-viral Drugs
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Treatment
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. HPV Associated Disorders Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. HPV Associated Disorders Market: Type Business Analysis

  • 4.1. Type Market Share, 2024 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Cervical Intraepithelial Neoplasia (CIN)
    • 4.4.1. Cervical Intraepithelial Neoplasia (CIN) Market, 2021 - 2033 (USD Million)
  • 4.5. Cervical Cancer
    • 4.5.1. Cervical Cancer Market, 2021 - 2033 (USD Million)
  • 4.6. Anal Intraepithelial Neoplasia (AIN)
    • 4.6.1. Anal Intraepithelial Neoplasia (AIN) Market, 2021 - 2033 (USD Million)
  • 4.7. Anal Cancer
    • 4.7.1. Anal Cancer Market, 2021 - 2033 (USD Million)
  • 4.8. Genital Warts
    • 4.8.1. Genital Warts Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. HPV Associated Disorders Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2033
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
  • 5.4. Vaccines
    • 5.4.1. Vaccines Market, 2021 - 2033 (USD Million)
  • 5.5. Anti-viral Drugs
    • 5.5.1. Anti-viral Drugs Market, 2021 - 2033 (USD Million)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. HPV Associated Disorders Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution channel, 2021 to 2033 (USD Million)
  • 6.4. Hospital Pharmacies
    • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacies
    • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. HPV Associated Disorders Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America HPV Associated Disorders Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Merck & Co., Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. GlaxoSmithKline plc
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. F. Hoffmann-La Roche Ltd
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Pfizer Inc.
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. AstraZeneca
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Biocon
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Lilly
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. AbbVie Inc.
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global HPV associated disorders market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 5 Global HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 6 Global HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 9 North America HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 10 North America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 12 U.S. HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 13 U.S. HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 15 Canada HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 16 Canada HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 18 Mexico HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 19 Mexico HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 22 Europe HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 23 Europe HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 25 UK HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 26 UK HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 28 Germany HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 29 Germany HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 31 France HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 32 France HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 34 Italy HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 35 Italy HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 37 Spain HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 38 Spain HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 40 Norway HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 41 Norway HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 43 Denmark HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 44 Denmark HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 46 Sweden HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 47 Sweden HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific HPV associated disorders market, by type, 2021 - 2033 (USD
  • Table 50 Asia Pacific HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 52 Japan HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 53 Japan HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 54 Japan HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 56 China HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 57 China HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 59 India HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 60 India HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 62 Australia HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 63 Australia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 65 South Korea HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 66 South Korea HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 68 Thailand HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 69 Thailand HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 72 Latin America HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 73 Latin America HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 75 Brazil HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 76 Brazil HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 78 Argentina HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 79 Argentina HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa HPV associated disorders market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 85 South Africa HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 86 South Africa HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 91 UAE HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 92 UAE HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait HPV associated disorders market, by type, 2021 - 2033 (USD Million)
  • Table 94 Kuwait HPV associated disorders market, by treatment, 2021 - 2033 (USD Million)
  • Table 95 Kuwait HPV associated disorders market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 HPV associated disorders market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 HPV associated disorders market dynamics
  • Fig. 12 HPV associated disorders market: Porter's five forces analysis
  • Fig. 13 HPV associated disorders market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Cervical Intraepithelial Neoplasia (CIN) market, 2021 - 2033 (USD Million)
  • Fig. 16 Cervical Cancer market, 2021 - 2033 (USD Million)
  • Fig. 17 Anal Intraepithelial Neoplasia (AIN) market, 2021 - 2033 (USD Million)
  • Fig. 18 Anal Cancer market, 2021 - 2033 (USD Million)
  • Fig. 19 Genital Warts market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Treatment market, 2021 - 2033 (USD Million)
  • Fig. 22 Vaccines market, 2021 - 2033 (USD Million)
  • Fig. 23 Anti-viral Drugs market, 2021 - 2033 (USD Million)
  • Fig. 24 Others market, 2021 - 2033 (USD Million)
  • Fig. 25 Distribution Channel market, 2021 - 2033 (USD Million)
  • Fig. 26 Hospital Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 27 Retail Pharmacies market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 HPV associated disorders market revenue, by region
  • Fig. 30 Regional marketplace: Key takeaways
  • Fig. 31 North America HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. country dynamics
  • Fig. 33 U.S. HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 34 Canada country dynamics
  • Fig. 35 Canada HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 36 Mexico country dynamics
  • Fig. 37 Mexico HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 38 Europe HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 39 UK country dynamics
  • Fig. 40 UK HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 41 Germany country dynamics
  • Fig. 42 Germany HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 43 France country dynamics
  • Fig. 44 France HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 45 Italy country dynamics
  • Fig. 46 Italy HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 47 Spain country dynamics
  • Fig. 48 Spain HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 49 Norway country dynamics
  • Fig. 50 Norway HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 51 Sweden country dynamics
  • Fig. 52 Sweden HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 53 Denmark country dynamics
  • Fig. 54 Denmark HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 55 Asia Pacific HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 56 Japan country dynamics
  • Fig. 57 Japan HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 58 China country dynamics
  • Fig. 59 China HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 60 India country dynamics
  • Fig. 61 India HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 62 Australia country dynamics
  • Fig. 63 Australia HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 64 South Korea country dynamics
  • Fig. 65 South Korea HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 66 Thailand country dynamics
  • Fig. 67 Thailand HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 68 Latin America HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 69 Brazil country dynamics
  • Fig. 70 Brazil HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 71 Argentina country dynamics
  • Fig. 72 Argentina HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 73 MEA HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 74 South Africa country dynamics
  • Fig. 75 South Africa HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 76 Saudi Arabia country dynamics
  • Fig. 77 Saudi Arabia HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 78 UAE country dynamics
  • Fig. 79 UAE HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 80 Kuwait country dynamics
  • Fig. 81 Kuwait HPV associated disorders market, 2021 - 2033 (USD Million)
  • Fig. 82 Company categorization
  • Fig. 83 Company market position analysis
  • Fig. 84 Strategic framework